![]() ![]() Type Small Molecule Groups Approved, Nutraceutical Structure This drug was initially approved by the FDA in 1942 Label. Several pharmaceutical forms of cyanocobalamin have been developed, including the tablet, injection, and nasal spray forms Label, 19, 20. The cyano form, is the most widely used form in supplements and prescription drugs 10, Label. Vitamin B12 has many forms, including the cyano-, methyl-, deoxyadenosyl- and hydroxy-cobalamin forms. This vitamin is produced naturally by bacteria 16, and is necessary for DNA synthesis and cellular energy production. 238000005804 alkylation reaction Methods 0.Animi-3 With Vitamin D, B-12, Cobex, Concept Ob, Dodex, Ferralet 90, Ferraplus, Folbic, Foltabs, Fortaplex, Hematogen, Infuvite, Infuvite Pediatric, Irospan 24/6 Kit, Mvc-fluoride, Mvi Pediatric, Nascobal, Natafort, Pregvit, Tandem Plus, Vitafol-one Generic Name CyanocobalaminĬommonly known or available as Vitamin B12 DrugBank Accession Number DB00115 BackgroundĬyanocobalamin (commonly known as Vitamin B12) is a highly complex, essential vitamin, owing its name to the fact that it contains the mineral, cobalt.230000015572 biosynthetic process Effects 0.000 claims description 21.-1 quaternary ammonium ions Chemical class 0.000 claims description 49.206010016803 Fluid overload Diseases 0.000 claims abstract description 4.206010007558 Cardiac failure chronic Diseases 0.000 claims abstract description 4.206010020772 Hypertension Diseases 0.000 claims abstract description 5.208000009863 Chronic Kidney Failure Diseases 0.000 claims abstract description 5.239000011258 core-shell material Substances 0.000 claims abstract description 98.239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 34.239000000203 mixture Substances 0.000 title claims abstract description 134.Publication of BRPI0509365A publication Critical patent/BRPI0509365A/en Publication of BRPI0509365B1 publication Critical patent/BRPI0509365B1/en Publication of BRPI0509365B8 publication Critical patent/BRPI0509365B8/en Links Priority to PCT/US2005/010747 priority patent/WO2005097072A1/en First worldwide family litigation filed litigation Critical (B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Family has litigation Priority to US10/814,749 priority Critical patent/US8192758B2/en Priority to US10/813,872 priority patent/US8282960B2/en Priority to US10/814,527 priority Priority to US10/813,872 priority Priority to US10/814,749 priority Priority to US10/814,527 priority patent/US7854924B2/en Priority to US10/965,274 priority patent/US7488495B2/en Priority to US10/965,274 priority Application filed by Relypsa, Inc. Priority date (The priority date is an assumption and is not a legal conclusion. Inventor Charmot Dominique Fordtran John Ting Chang Han Connor Eric Liu Mingjun Klaerner Gerrit Original Assignee Relypsa, Inc. Pharmaceutical composition, pharmaceutical kit, and use of said compositionĭownload PDF Info Publication number BRPI0509365B1 BRPI0509365B1 BRPI0509365-1A BRPI0509365A BRPI0509365B1 BR PI0509365 B1 BRPI0509365 B1 BR PI0509365B1 BR PI0509365 A BRPI0509365 A BR PI0509365A BR PI0509365 B1 BRPI0509365 B1 BR PI0509365B1 Authority BR Brazil Prior art keywords shell core pharmaceutical composition polymer compositions Prior art date Application number BRPI0509365-1A Other languages Portuguese ( pt)
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |